Opinion|Videos|January 20, 2025
Final Thoughts on Identifying and Managing Patients with T1D
Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5